Larox plans Chinese subsidiary

Larox plans Chinese subsidiary

NEWS/EXCHANGE RATES With existing machinery and personnel, Camfil Farr can now produce more than one million pocket filters per year in Slovakia. This...

65KB Sizes 22 Downloads 91 Views

NEWS/EXCHANGE RATES With existing machinery and personnel, Camfil Farr can now produce more than one million pocket filters per year in Slovakia. This is based on a two-shift operation.

Camfil Farr expands in China and Slovakia

C

amfil Farr has opened new production plants in Kunshan, near Shanghai, China and in Levice, Slovakia. Camfil Farr Filtration Kunshan Ltd’s new 11 000 m2 factory in Kunshan is designed for the full-scale production of HVAC and HEPA/ULPA filters. All manufacturing at Camfil Farr’s original plant in the area has now been transferred to the new Kunshan facility. The locally manufactured product portfolio in China used to be limited to filters for the comfort air sector, but now mini pleat and HEPA/ULPA filters have been added to the Kunshan facility to meet the strong demand for clean process air from China’s expanding industrial base. The mini pleat filters are manufactured in cleanroom conditions in Kunshan. The plant has also been equipped with a pleater for HEPA/ULPA filter media, a computerized auto scanner for 100% finished product testing and a robotic endless gasket machine. Camfil Farr’s recently opened production plant in Levice, Slovakia will manufacture products for existing European markets and emerging East European markets. The current building in Levice is 9000 m² but can be expanded by another 15 000 m² as the plant’s production needs increase.

For further information, visit www.camfilfarr.com

Larox plans Chinese subsidiary

L

arox is setting up a subsidiary in Shanghai for filter sales and after market services in China. The subsidiary will purchase components from local suppliers. Larox also plans to start local assembly of filters, primarily for the Chinese and Asian markets during the first half of 2009. “The planned establishment of [a] subsidiary aims at improving our ability to serve current and new customers in the growing Chinese and Asian markets. We believe that access to local markets with full product portfolio supported by local assembly and sourcing will improve our competitiveness globally and strengthen our position as a supplier of solid/liquid separation solutions for customers in mining, metallurgical and chemical process industries,” said Topi Karppanen, president and CEO of Larox. Until now, Larox has operated in China through an agent.

For further information, visit www.larox.com

Exchange Rates against the US Dollar Date: 7.2.2008 Country Australia

Rate A$1.12

Country Netherlands

Rate 0.69

Austria

0.69

Norway

Belgium

0.69

Philippines

Canada

C$1.01

Singapore

Yn7.19

South Africa

R7.65

DKr5.15

South Korea

KWn941.60

China Denmark

NKr5.56 Peso40.64 S$1.42

0.69

Finland

0.69

Spain

France

0.69

Sweden

0.69

Switzerland

SFr1.11

Taiwan

T$32.02

Thailand

Bt31.28

Germany India Italy Japan Malaysia

16

Filtration Industry Analyst

Rs39.62 0.69 ¥107.71 Rt3.23

UK USA

SKr6.52

£0.51

Editorial Office: Elsevier Limited The Boulevard, Langford Lane Kidlington Oxford OX5 1GB United Kingdom Tel: +44 (0)1865 843695 Fax: +44 (0)1865 843971 E-mail: [email protected] Web: www.filtrationindustryanalyst.com Editor: Roisin Reidy Production Editor: Alan Stubley Subscription Information An annual subscription to Filtration Industry Analyst includes 12 printed issues and online access for up to 5 users. Prices: 1049 for all European countries & Iran US$1176 for all countries except Europe and Japan ¥139 400 for Japan (Prices valid until 31 December 2008) To subscribe send payment to the address above. Tel: +44 (0)1865 843687/Fax: +44 (0)1865 834971 E-mail: [email protected], or via www.filtrationindustryanalyst.com. Subscriptions run for 12 months, from the date payment is received. Periodicals postage is paid at Rahway, NJ 07065, USA. Postmaster send all USA address corrections to: Filtration Industry Analyst, 365 Blair Road, Avenel, NJ 07001, USA Permissions may be sought directly from Elsevier Global Rights Department, PO Box 800, Oxford OX5 1DX, UK; phone: +44 1865 843830, fax: +44 1865 853333, e-mail: [email protected] You may also contact Global Rights directly through Elsevier’s home page (www.elsevier.com), selecting first ‘Support & contact’, then ‘Copyright & permission’. In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: +1 978 750 8400, fax: +1 978 750 4744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: +44 (0)20 7631 5555; fax: +44 (0)20 7631 5500. Other countries may have a local reprographic rights agency for payments. Derivative Works Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution. Permission of the Publisher is required for all other derivative works, including compilations and translations. Electronic Storage or Usage Permission of the Publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher. Address permissions requests to: Elsevier Science Global Rights Department, at the mail, fax and e-mail addresses noted above. Notice No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

Printed by Mayfield Press (Oxford) LImited 02207

US$1.00

March 2008